使用PSMA PET/CT评估转移性去势抵抗性前列腺癌的治疗反应:RECIST 1.1、aPCWG3、aPERCIST、PPP与RECIP 1.0标准的比较
该多中心回顾性研究纳入124例接受177Lu-PSMA放射性配体治疗的mCRPC患者,于基线和12周行PSMA-PET/CT,比较五种反应标准。RECIP 1.0识别的进展患者最少且进展 vs 无进展的死亡风险最高(HR=4.33),PSMA-PET特异性标准的预后价值和阅片者间可靠性均优于传统CT评估。
要点
- RECIP 1.0识别PD患者39例(32%),进展 vs 无进展的死亡风险HR=4.33(95%CI 2.80-6.70,p<0.001)。
- RECIST 1.1评估中43例(35%)为不可测量病灶,其PD vs 无进展的死亡风险无显著差异(HR=1.29,95%CI 0.73-2.27,p=0.38)。
- RECIP 1.0的阅片者间κ指数最高(0.83),其次为PPP(0.73)和aPCWG3(0.72)。
核心结论
- PSMA-PET特异性标准在177Lu-PSMA治疗的mCRPC患者早期反应评估中,较传统CT评估或其他影像模态改编至PSMA-PET的标准,获得更高的预后价值和阅片者间可靠性。
- RECIP 1.0识别的PD患者最少,且PD vs 无进展的死亡风险最高,提示其他分类方法倾向于过度判定进展。
- 作者认为需要在独立患者队列中对本研究发现进行前瞻性验证。
研究设计与样本
- 多中心回顾性研究,共纳入124例接受177Lu-PSMA放射性配体治疗的转移性去势抵抗性前列腺癌(mCRPC)患者。
- 所有患者于基线(bPET)和12周(iPET)行PSMA-PET/CT扫描。
- 由三名设盲阅片者共识判读RECIST 1.1、aPCWG3、aPERCIST、PPP和RECIP 1.0的影像反应,并使用半自动qPSMA软件获取总肿瘤负荷变化。
- 主要结局指标为总生存期(OS)的预后价值(Cox回归分析),次要结局指标为阅片者间可靠性(Cohen's κ系数)。
主要发现
- 124例患者中,43例(35%)根据RECIST 1.1为不可测量病灶。
- RECIST 1.1、aPCWG3、aPERCIST、PPP和RECIP分别有16例(13%)、66例(52%)、72例(58%)、69例(56%)和39例(32%)患者判定为PD。
- PD vs 无PD的死亡风险:aPCWG3 HR=2.37(95%CI 1.62-3.48,p<0.001),aPERCIST HR=2.48(95%CI 1.68-3.66,p<0.001),PPP HR=2.72(95%CI 1.85-4.01,p<0.001),RECIP 1.0 HR=4.33(95%CI 2.80-6.70,p<0.001),RECIST 1.1 HR=1.29(95%CI 0.73-2.27,p=0.38)无显著差异。
- 识别PD vs 无PD的κ指数:RECIST 1.1为0.50(95%CI 0.32-0.76),aPCWG3为0.72(95%CI 0.63-0.82),aPERCIST 1.0为0.68(95%CI 0.63-0.73),PPP为0.73(95%CI 0.63-0.83),RECIP 1.0为0.83(95%CI 0.77-0.88)。
关键数值与推荐
- RECIP 1.0:PD 39/124例(32%),PD vs 无PD的死亡风险HR=4.33(95%CI 2.80-6.70,p<0.001),κ=0.83(95%CI 0.77-0.88)。
- PPP:PD 69/124例(56%),PD vs 无PD的死亡风险HR=2.72(95%CI 1.85-4.01,p<0.001),κ=0.73(95%CI 0.63-0.83)。
- aPCWG3:PD 66/124例(52%),PD vs 无PD的死亡风险HR=2.37(95%CI 1.62-3.48,p<0.001),κ=0.72(95%CI 0.63-0.82)。
- aPERCIST:PD 72/124例(58%),PD vs 无PD的死亡风险HR=2.48(95%CI 1.68-3.66,p<0.001),κ=0.68(95%CI 0.63-0.73)。
- RECIST 1.1:PD 16/124例(13%),43例(35%)为不可测量病灶,PD vs 无PD的死亡风险HR=1.29(95%CI 0.73-2.27,p=0.38)无显著差异,κ=0.50(95%CI 0.32-0.76)。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 作者认为需要在独立患者队列中对本研究发现进行前瞻性验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To compare the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, the adapted Prostate Cancer Working Group Criteria 3 (aPCWG3), the adapted Positron Emission Tomography Response Criteria in Solid Tumors (aPERCIST), the PSMA PET Progression (PPP), and the Response Evaluation Criteria In PSMA-Imaging (RECIP) 1.0 for response evaluation using prostate-specific membrane antigen (PSMA)-PET/CT in men with metastatic castration-resistant prostate cancer (mCRPC) treated with 177Lu-PSMA radioligand therapy. METHODS: A total of 124 patients were included in this multicenter retrospective study. All patients received 177Lu-PSMA and underwent PSMA-PET/CT scans at baseline (bPET) and at 12 weeks (iPET). Imaging responses according to RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 were interpreted by consensus among three blinded readers. Changes in total tumor burden were obtained using the semi-automatic qPSMA software. The response according to each criterion was classified to progressive disease (PD) vs no-PD. Primary outcome measure was the prognostic value (by Cox regression analysis) for overall survival (OS). Secondary outcome measure was the inter-reader reliability (by Cohen's κ coefficient). RESULTS: A total of 43 (35%) of patients had non-measurable disease according to RECIST 1.1. Sixteen (13%), 66 (52%), 72 (58%), 69 (56%), and 39 (32%) of 124 patients had PD according to RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP, respectively. PD vs no-PD had significantly higher risk of death according to aPCWG3 (HR = 2.37; 95%CI, 1.62-3.48; p < 0.001), aPERCIST (HR = 2.48; 95%CI, 1.68-3.66; p < 0.001), PPP (HR = 2.72; 95%CI, 1.85-4.01; p < 0.001), RECIP 1.0 (HR = 4.33; 95%CI, 2.80-6.70; p < 0.001), but not according to RECIST 1.1 (HR = 1.29; 95%CI, 0.73-2.27; p = 0.38). The κ index of RECIST 1.1, aPCWG3, aPERCIST 1.0, PPP, and RECIP 1.0 for identifying PD vs no-PD were 0.50 (95%CI, 0.32-0.76), 0.72 (95%CI, 0.63-0.82), 0.68 (95%CI, 0.63-0.73), 0.73 (95%CI, 0.63-0.83), and 0.83 (95%CI, 0.77-0.88), respectively. CONCLUSION: PSMA-PET-specific criteria for early response evaluation in men with mCRPC treated with 177Lu-PSMA achieved higher prognostic values and inter-reader reliabilities in comparison to conventional CT assessment or to criteria adapted to PSMA-PET from other imaging modalities. RECIP 1.0 identified the fewest patients with PD and achieved the highest risk of death for PD vs. no-PD, suggesting that other classification methods tend to overcall progression. Prospective validation of our findings on an independent patient cohort is warranted.
引用
- Gafita A, Rauscher I, Fendler WP, et al. Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria. Eur J Nucl Med Mol Imaging. 2022. PMID: 35767071. doi:10.1007/s00259-022-05882-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。